The company’s new AstraZeneca AstraVio skin-care range, which has already sold more than 5.3 million units worldwide, is aimed at boosting vitamin D and reducing the risk of skin cancer.
In a study published online in the Journal of the American Medical Association (JAMA), researchers at the University of New South Wales and the University in Sydney found that the Astra Zensa skin-cure products significantly reduced the risk for developing skin cancer by almost 50 per cent compared to a placebo.
The study, which involved more than 1,200 people with skin cancer and was conducted between July 2018 and February 2019, found that patients taking the Astrakhan skin-scrub, Astra Zeneca’s AstraVege skin-cream, or AstraCure skin-lightening cream had a 25 per cent reduction in their risk of developing melanoma, while those taking the placebo skin-tanning cream had no change in their skin-cancer risk.
“While previous studies have found skin cancer is a relatively common disease, our study found that it is particularly challenging to determine a clinically meaningful benefit from using topical vitamin D therapies,” said Dr Michelle Taylor, who led the research from the Australian National University’s School of Health Sciences.
“There is a lack of evidence that topical vitamin d3 or its derivatives reduce the risk or increase the likelihood of melanoma in people.”
While AstraMedicine skin-cleansers can be taken as a daily treatment, the skin-treatment product is intended for use in the evening.
Dr Taylor said the study showed the topical Astra-Zeneca Astrakyan skin-tanners were “highly effective” for reducing the incidence of melanomas.
The Astrazeneca skin-lotion AstraBiosciences skin-friendly skin-balm is also available in Australia.
The company said the Astragalax skin-sensitiser, which can be used twice a day, was “well tolerated and does not cause skin irritation”.
The Astrakanac skin-protector AstraGarden skin-softening cream has also been sold to a limited number of customers in Australia and the US, and has been shown to be effective in reducing melanoma risk in a number of clinical trials.
“The AstraGuard Skin Softener has a proven track record in reducing the melanoma rates of skin cancers and skin cancer-specific mortality in melanoma patients in clinical trials,” said Astra Medicine’s chief executive officer, Dr Joanne Ayliffe.
“We continue to explore the best uses of skin-health products for skin-conditioning and the Astravan skin-brightening cream is an excellent option to use as a facial mask, for example.”